Subtype
Early Stage Breast Carcinoma
CI-CAN-00002563Explore in graph →
57 active trials2 approved drugs
- NCIt
- C94774
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002563Explore in graph →
Clinical trials
145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03077841 | Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer | suspended | Phase 2 / Phase 3 | 928 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06144944 | Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer | active not recruiting | Phase 3 | 160 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 18, 2026 |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | recruiting | Phase 3 | 1,295 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 5, 2026 | clinicaltrials |
| NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy(PLANET) | not yet recruiting | Phase 3 | 1,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT07483996 | Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer(CRYSTAL) | not yet recruiting | Phase 3 | 938 | Franciscus Gasthuis & Vlietland (Hospital)OTHER | 0 | Mar 19, 2026 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06152471 | Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer(ASF-BC) | unknown | Phase 3 | 100 | Henrik LindmanOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT00309478 | Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients | completed | Phase 3 | 1,099 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Jun 29, 2023 | clinicaltrials |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | completed | Phase 3 | 338 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Oct 26, 2022 | clinicaltrials |
| NCT00309491 | Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients | completed | Phase 3 | 2,021 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 19, 2020 | clinicaltrials |
| NCT00309569 | Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients | completed | Phase 3 | 429 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 14, 2020 | clinicaltrials |
| NCT02568839 | Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer(PREDIX HER2) | active not recruiting | Phase 2 / Phase 3 | 202 | Thomas HatschekOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT02958033 | Shandong Cancer Hospital Affiliated to Shandong University | unknown | Phase 3 | 100 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 8, 2016 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials